• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Respiratory/Inflammation

The following trials provide information to treat various types of respiratory and inflammatory diseases, both for ongoing and completed clinical trials.  For more information on both of these therapy areas please click here.

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.

  • Expand All
  • Collapse All
  • Pages
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • collapse A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects with Moderate to Severe Hidradenitis Suppurativa
  • collapse The asthma control rate achieved by budesonide/formoterol in clinical practice in China
  • collapse Oxis 9mcg Turbuhaler Clinical Experience Investigation
  • collapse Perception of symptom variability in Chinese COPD patients
  • collapse Clinical Experience Investigation for treatment with Symbicort as maintenance therapy and as needed in response to symptoms
  • collapse Symbicort Turbulaler 30/60 Special Clinical Experince Investigation for long-term use for COPD patients
  • collapse A Phase 2, Open-Label Extension Study to Evaluate Long-Term Safety of MEDI-546 in Adults with Systemic Lupus Erythematosus
  • collapse A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study with an Optional Safety Extension Treatment Period up to 6 months, to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting β2 Agonists (LABA), in Patients with Uncontrolled Persistent Asthma
  • collapse An Observational Study to Assess Respiratory Syncytial Virus (RSV)-Associated Illness in Adults with Chronic Obstructive Pulmonary Disease (COPD) and/or Congestive Heart Failure (CHF)
  • collapse A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of MEDI-557 in Healthy Adults Intranasally Challenged with Respiratory Syncytial Virus (RSV)
  • Pages
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013